Loading...
Programmed Cell Death One Inhibition Therapy in Classical Hodgkin Lymphoma
The majority of patients with classical Hodgkin lymphoma (cHL) may be cured, but for patients with relapsed or refractory (R/R) cHL, the prognosis is unfavorable. Immune dysfunction is a significant contributor of relapse and a hallmark of cHL, in particular, the immune system unable of destroying l...
Na minha lista:
| Udgivet i: | Clin Lymphoma Myeloma Leuk |
|---|---|
| Main Authors: | , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
2020
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7878303/ https://ncbi.nlm.nih.gov/pubmed/33160934 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clml.2020.08.031 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|